Biovie (BIVI) EBITDA (2013 - 2026)

Biovie has disclosed EBITDA across 12 years of filings, most recently posting -$5.7 million for Q2 2026.

• In Q2 2026, EBITDA fell 56.14% year-over-year to -$5.7 million; the TTM figure through Jun 2026 stood at -$22.7 million (down 25.38% YoY), while the FY2026 annual figure was -$22.7 million, down 25.38% from the prior year.
• EBITDA came in at -$5.7 million for Q2 2026 at Biovie, down from -$5.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$3.0 million in Q1 2025 to a low of -$13.8 million in Q1 2023.
• Average EBITDA over 5 years is -$7.4 million, with a median of -$6.8 million recorded in 2024.
• Year-over-year, EBITDA jumped 92.94% in 2022 and sank 139.61% in 2023.
• Over 5 years, EBITDA stood at -$11.5 million in 2022, then increased by 23.61% to -$8.8 million in 2023, then increased by 16.95% to -$7.3 million in 2024, then grew by 14.13% to -$6.3 million in 2025, then gained by 8.67% to -$5.7 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$5.7 million in Q2 2026, -$5.4 million in Q1 2026, and -$6.3 million in Q4 2025.